In Vitro & In Vivo Diagnostic Substances
Standard Industrial Classification: SIC 2835
Industry Insider Sentiment Analysis
The In Vitro & In Vivo Diagnostic Substances sector (SIC 2835) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-04-14 23:30 | 2021-04-12 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director, Officer | SELL | $20.66 | 19,421 | $401,277 | 703,762 |
| 2021-04-15 01:18 | 2021-04-14 | NEOG | NEOGEN CORP | Quinlan Steven J. | Officer | OPT+S | $93.93 | 13,001 | $1,221,153 | 13,470 |
| 2021-04-13 23:30 | 2021-04-09 | LNTH | Lantheus Holdings, Inc. | McHugh Julie | Director | SELL | $21.22 | 2,800 | $59,416 | 23,057 |
| 2021-04-12 23:30 | 2021-04-08 | LNTH | Lantheus Holdings, Inc. | LENO SAM R | Director | SELL | $21.17 | 5,000 | $105,840 | 40,784 |
| 2021-04-07 21:14 | 2021-04-05 | NTLA | Intellia Therapeutics, Inc. | FORMELA JEAN FRANCOIS | Director | SELL | $84.98 | 800 | $67,984 | 1,112,576 |
| 2021-04-07 01:09 | 2021-04-05 | NTLA | Intellia Therapeutics, Inc. | DORSA CAROLINE | Director | OPT+S | $82.19 | 7,500 | $616,405 | 5,410 |
| 2021-04-06 01:36 | 2021-03-31 | NEOG | NEOGEN CORP | MORRICAL TERRI A | OPT+S | $88.03 | 31,401 | $2,764,230 | 37,575 | |
| 2021-04-03 03:42 | 2021-04-01 | NTLA | Intellia Therapeutics, Inc. | Rivera Jose E | Officer | OPT+S | $82.46 | 50,455 | $4,160,560 | 162,388 |
| 2021-04-03 03:46 | 2021-04-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | OPT+S | $83.64 | 38,209 | $3,195,659 | 693,368 |
| 2021-04-02 04:19 | 2021-03-31 | NEOG | NEOGEN CORP | ADENT JOHN EDWARD | Director, Officer | OPT+S | $87.99 | 40,464 | $3,560,395 | 20,080 |
| 2021-04-02 01:40 | 2021-03-30 | NEOG | NEOGEN CORP | ADENT JOHN EDWARD | Director, Officer | OPT+S | $87.09 | 9,536 | $830,486 | 20,080 |
| 2021-04-02 03:56 | 2021-03-31 | NEOG | NEOGEN CORP | Quinlan Steven J. | Officer | OPT+S | $88.07 | 15,000 | $1,321,058 | 13,470 |
| 2021-04-02 01:11 | 2021-03-31 | NEOG | NEOGEN CORP | BOEHM WILLIAM T | Director | OPT+S | $88.25 | 2,000 | $176,500 | 10,479 |
| 2021-04-01 02:16 | 2021-03-29 | NEOG | NEOGEN CORP | MORRICAL TERRI A | OPT+S | $87.99 | 600 | $52,795 | 37,575 | |
| 2021-03-31 01:31 | 2021-03-29 | MYGN | MYRIAD GENETICS INC | Hart Jayne B. | Officer | OPT+S | $30.00 | 58,000 | $1,740,000 | 80,128 |
| 2021-03-26 22:46 | 2021-03-25 | NEOG | NEOGEN CORP | PAPESH BRUCE | Director | OPT+S | $85.42 | 7,000 | $597,957 | 36,261 |
| 2021-03-23 00:17 | 2021-03-19 | OCX | Insight Molecular Diagnostics Inc. | ANDREWS RONALD ASBURY | Director, Officer | BUY | $4.79 | 11,000 | $52,702 | 113,698 |
| 2021-03-10 05:07 | 2021-03-05 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $18.60 | 1,000 | $18,600 | 16,211 |
| 2021-03-10 05:06 | 2021-03-05 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Director, Officer | SELL | $18.26 | 27,157 | $495,838 | 711,720 |
| 2021-03-09 05:09 | 2021-03-04 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Officer | SELL | $18.40 | 4,061 | $74,722 | 26,509 |
| 2021-03-09 05:07 | 2021-03-04 | LNTH | Lantheus Holdings, Inc. | Bolla John J. | Officer | SELL | $18.40 | 1,887 | $34,721 | 57,345 |
| 2021-03-09 04:48 | 2021-03-04 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $18.40 | 2,280 | $41,952 | 76,985 |
| 2021-03-09 04:40 | 2021-03-04 | LNTH | Lantheus Holdings, Inc. | Molnar Istvan | Officer | SELL | $18.40 | 4,027 | $74,097 | 25,130 |
| 2021-03-09 05:05 | 2021-03-04 | LNTH | Lantheus Holdings, Inc. | DUFFY MICHAEL P | Officer | SELL | $18.97 | 6,769 | $128,379 | 116,972 |
| 2021-03-04 00:30 | 2021-03-01 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | Officer | SELL | $19.08 | 1,465 | $27,955 | 79,265 |
| 2021-03-04 00:30 | 2021-03-01 | LNTH | Lantheus Holdings, Inc. | Bolla John J. | Officer | SELL | $19.08 | 1,187 | $22,650 | 59,232 |
| 2021-03-04 00:30 | 2021-03-01 | LNTH | Lantheus Holdings, Inc. | DUFFY MICHAEL P | Officer | SELL | $19.08 | 1,473 | $28,108 | 101,929 |
| 2021-03-03 00:30 | 2021-02-26 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $18.02 | 1,000 | $18,020 | 15,211 |
| 2021-03-01 21:59 | 2021-02-26 | NTLA | Intellia Therapeutics, Inc. | FORMELA JEAN FRANCOIS | Director | SELL | $60.29 | 501,945 | $30,262,716 | 1,113,376 |
| 2021-02-26 03:35 | 2021-02-23 | IDXX | IDEXX LABORATORIES INC /DE | HENDERSON REBECCA M | Director | OPT+S | $513.41 | 3,046 | $1,563,840 | 14,696 |
| 2021-02-25 01:00 | 2021-02-22 | IDXX | IDEXX LABORATORIES INC /DE | JUNIUS DANIEL M | Director | OPT+S | $538.57 | 1,898 | $1,022,207 | 2,875 |
| 2021-02-24 00:30 | 2021-02-19 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $19.39 | 1,000 | $19,390 | 14,211 |
| 2021-02-23 02:00 | 2021-02-18 | IDXX | IDEXX LABORATORIES INC /DE | AYERS JONATHAN W | Director | OPT+S | $555.56 | 1,000 | $555,561 | 652,737 |
| 2021-02-20 01:00 | 2021-02-17 | IDXX | IDEXX LABORATORIES INC /DE | MAZELSKY JONATHAN JAY | Director, Officer | OPT+S | $537.21 | 13,868 | $7,449,969 | 54,222 |
| 2021-02-19 03:26 | 2021-02-16 | IDXX | IDEXX LABORATORIES INC /DE | Claflin Bruce L. | Director | OPT+S | $536.91 | 7,331 | $3,936,089 | 0 |
| 2021-02-18 03:31 | 2021-02-16 | IDXX | IDEXX LABORATORIES INC /DE | Lane Michael | Officer | OPT+S | $545.00 | 850 | $463,250 | 3,624 |
| 2021-02-18 00:30 | 2021-02-12 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $20.03 | 1,000 | $20,030 | 13,211 |
| 2021-02-18 03:33 | 2021-02-16 | IDXX | IDEXX LABORATORIES INC /DE | MCKEON BRIAN P | Officer | OPT+S | $539.58 | 1,307 | $705,231 | 24,714 |
| 2021-02-18 02:10 | 2021-02-16 | MYGN | MYRIAD GENETICS INC | LANCHBURY JERRY S | Officer | OPT+S | $29.71 | 80,000 | $2,377,048 | 246,575 |
| 2021-02-17 01:00 | 2021-02-12 | IDXX | IDEXX LABORATORIES INC /DE | Vandebroek Sophie V. | Director | OPT+S | $538.20 | 3,046 | $1,639,357 | 3,321 |
| 2021-02-10 04:38 | 2021-02-09 | NTLA | Intellia Therapeutics, Inc. | Rivera Jose E | Officer | OPT+S | $75.00 | 11,489 | $861,675 | 117,920 |
| 2021-02-10 04:36 | 2021-02-05 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | OPT+S | $71.70 | 50,985 | $3,655,410 | 660,536 |
| 2021-02-10 00:30 | 2021-02-05 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $17.94 | 1,000 | $17,940 | 12,211 |
| 2021-02-10 01:21 | 2021-02-05 | OCX | Insight Molecular Diagnostics Inc. | BROADWOOD PARTNERS, L.P. | 10% owner | BUY | $4.50 | 600,000 | $2,700,000 | 16,776,484 |
| 2021-02-08 22:31 | 2021-02-05 | NEOG | NEOGEN CORP | Lilly Jason Warren | Officer | SELL | $85.23 | 2,265 | $193,052 | 11,346 |
| 2021-02-09 00:06 | 2021-02-05 | VNRX | VOLITIONRX LTD | TERRELL JASON BRADLEY MD | Officer | SELL | $5.37 | 10,000 | $53,700 | 34,949 |
| 2021-02-09 02:05 | 2021-02-04 | IDXX | IDEXX LABORATORIES INC /DE | SZOSTAK M ANNE | Director | OPT+S | $489.71 | 11,876 | $5,815,816 | 0 |
| 2021-02-04 05:38 | 2021-02-01 | NTLA | Intellia Therapeutics, Inc. | Rivera Jose E | Officer | OPT+S | $64.00 | 54,659 | $3,497,903 | 108,409 |
| 2021-02-04 05:39 | 2021-02-01 | NTLA | Intellia Therapeutics, Inc. | LEONARD JOHN M | Director, Officer | OPT+S | $67.26 | 177,745 | $11,955,395 | 614,803 |
| 2021-02-03 00:30 | 2021-01-29 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Director | BUY | $16.13 | 1,000 | $16,130 | 11,211 |
Sector-Wide Insider Alpha
Analyzing insider movements across the In Vitro & In Vivo Diagnostic Substances sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2835) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in In Vitro & In Vivo Diagnostic Substances
Every transaction in the In Vitro & In Vivo Diagnostic Substances industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.